Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

• Main Authors: Victor Sokolov (Author), Tatiana Yakovleva (Author), Lulu Chu (Author), Weifeng Tang (Author), Peter J. Greasley (Author), Susanne Johansson (Author), Kirill Peskov (Author), Gabriel Helmlinger (Author), David W. Boulton (Author), Robert C. Penland (Author)
• Format: Book
• Published: Wiley, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative systems pharmacology model of renal glucose filtrati...